Drugs & Targets FDA accepts BLA for Tevimbra for 1L treatment of G/GEJ cancers March 01, 2024Vol.50 No.09
Drugs & Targets Lixte Biotechnology enters exclusive immuno-oncology patent license agreement with NINDS, NCI March 01, 2024Vol.50 No.09
Drugs & Targets Exact Sciences launches Riskguard hereditary cancer test in the U.S. March 01, 2024Vol.50 No.09
Drugs & Targets Linvoseltamab BLA accepted for Priority Review for R/R multiple myeloma February 23, 2024Vol.50 No.08
Drugs & Targets FDA OCE annual report lists 83 cancer therapeutic approvals in 2023 February 23, 2024Vol.50 No.08
Drugs & Targets Mainz Biomed and Praxisdienst form distribution partnership for ColoAlert February 23, 2024Vol.50 No.08
Drugs & Targets FDA approves Onivyde for first-line treatment of metastatic pancreatic adenocarcinoma February 16, 2024Vol.50 No.07
Drugs & Targets FDA grants Augtyro priority review for NTRK-positive locally advanced or metastatic solid tumors February 16, 2024Vol.50 No.07
Drugs & Targets MD Anderson, C-Biomex sign collaborative research agreement to co-develop CBT-001 radioligand therapy February 16, 2024Vol.50 No.07
